Medexus Pharmaceuticals Inc
TSX:MDP
Balance Sheet
Balance Sheet Decomposition
Medexus Pharmaceuticals Inc
Medexus Pharmaceuticals Inc
Balance Sheet
Medexus Pharmaceuticals Inc
| Dec-2011 | Dec-2012 | Mar-2014 | Mar-2015 | Mar-2016 | Mar-2017 | Mar-2018 | Mar-2019 | Mar-2020 | Mar-2021 | Mar-2022 | Mar-2023 | Mar-2024 | Mar-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||
| Cash & Cash Equivalents |
0
|
1
|
7
|
7
|
5
|
3
|
4
|
29
|
5
|
19
|
10
|
13
|
5
|
24
|
|
| Cash |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Cash Equivalents |
0
|
1
|
7
|
7
|
5
|
3
|
4
|
29
|
5
|
19
|
10
|
13
|
5
|
24
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
10
|
15
|
19
|
14
|
22
|
24
|
13
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
10
|
15
|
18
|
13
|
22
|
24
|
13
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
|
| Inventory |
0
|
0
|
0
|
0
|
1
|
2
|
2
|
6
|
14
|
15
|
21
|
23
|
31
|
35
|
|
| Other Current Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
5
|
6
|
3
|
15
|
12
|
8
|
|
| Total Current Assets |
0
|
1
|
8
|
8
|
6
|
6
|
7
|
47
|
40
|
59
|
49
|
73
|
72
|
81
|
|
| PP&E Net |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| PP&E Gross |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| Intangible Assets |
0
|
1
|
1
|
1
|
2
|
2
|
3
|
56
|
70
|
76
|
77
|
70
|
64
|
72
|
|
| Goodwill |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
9
|
10
|
11
|
11
|
10
|
10
|
10
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
2
|
2
|
7
|
8
|
9
|
|
| Other Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
9
|
10
|
11
|
11
|
10
|
10
|
10
|
|
| Total Assets |
0
N/A
|
2
+325%
|
9
+406%
|
9
+6%
|
8
-15%
|
8
N/A
|
9
+21%
|
114
+1 120%
|
123
+8%
|
149
+21%
|
139
-6%
|
161
+16%
|
156
-3%
|
172
+10%
|
|
| Liabilities | |||||||||||||||
| Accounts Payable |
0
|
0
|
1
|
1
|
1
|
2
|
2
|
14
|
9
|
15
|
12
|
10
|
8
|
6
|
|
| Accrued Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
13
|
13
|
17
|
23
|
35
|
35
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
10
|
11
|
15
|
43
|
16
|
37
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
2
|
4
|
7
|
7
|
19
|
|
| Total Current Liabilities |
0
|
1
|
1
|
1
|
1
|
2
|
2
|
14
|
34
|
40
|
48
|
83
|
66
|
97
|
|
| Long-Term Debt |
0
|
2
|
0
|
4
|
4
|
4
|
4
|
23
|
29
|
34
|
40
|
27
|
34
|
0
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
8
|
7
|
3
|
2
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
8
|
0
|
0
|
0
|
0
|
0
|
32
|
29
|
54
|
32
|
28
|
25
|
22
|
|
| Total Liabilities |
0
N/A
|
11
N/A
|
1
-87%
|
5
+229%
|
5
+4%
|
6
+33%
|
6
-3%
|
76
+1 131%
|
99
+29%
|
131
+32%
|
121
-7%
|
139
+14%
|
125
-10%
|
120
-5%
|
|
| Equity | |||||||||||||||
| Common Stock |
0
|
0
|
21
|
21
|
21
|
21
|
25
|
62
|
45
|
67
|
69
|
69
|
76
|
96
|
|
| Retained Earnings |
0
|
10
|
15
|
20
|
22
|
24
|
27
|
34
|
34
|
62
|
65
|
64
|
64
|
62
|
|
| Additional Paid In Capital |
0
|
1
|
1
|
3
|
4
|
4
|
5
|
8
|
7
|
10
|
10
|
11
|
12
|
12
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
7
|
4
|
4
|
6
|
6
|
6
|
|
| Total Equity |
0
N/A
|
9
N/A
|
7
N/A
|
5
-38%
|
3
-38%
|
1
-54%
|
3
+131%
|
37
+1 140%
|
24
-35%
|
18
-26%
|
18
-1%
|
22
+26%
|
30
+35%
|
52
+72%
|
|
| Total Liabilities & Equity |
0
N/A
|
2
+325%
|
9
+406%
|
9
+6%
|
8
-15%
|
8
N/A
|
9
+21%
|
114
+1 120%
|
123
+8%
|
149
+21%
|
139
-6%
|
161
+16%
|
156
-3%
|
172
+10%
|
|
| Shares Outstanding | |||||||||||||||
| Common Shares Outstanding |
0
|
1
|
5
|
5
|
5
|
5
|
6
|
15
|
15
|
19
|
20
|
20
|
24
|
32
|
|